Venus Concept Inc.

Company Overview

Business Model: Venus Concept Inc. is a global medical technology company that develops, commercializes, and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies and related services. The Company's systems are designed on cost-effective, proprietary, and flexible platforms, enabling expansion beyond traditional aesthetic markets (dermatology, plastic surgery) into non-traditional markets, including family medicine, general practitioners, and aesthetic medical spas. In 2024 and 2023, a substantial majority of systems delivered in North America were to non-traditional markets. Revenue is generated from product sales (systems, marketing supplies, consumables, replacement applicators/handpieces) and service revenue (extended warranty contracts). Systems are sold through traditional sales, internal financing programs (Venus Prime, legacy subscription), and distributors.

Market Position: The Company operates in the large, growing, and global aesthetic and hair restoration markets. The global aesthetic procedures market saw approximately 35 million cosmetic procedures worldwide in 2023, with 19.2 million being non-surgical. The global market for surgical hair restoration treatments totaled an estimated $4.5 billion in 2021. Venus Concept Inc. aims to expand its market by offering proprietary technologies like (MP)2 for non-invasive treatments and robotic systems such as ARTAS and AI.ME for hair restoration and fractional skin resurfacing. Key competitive advantages include expanding market access through internal financing programs like Venus Prime, maintaining strong customer relationships through a "high-touch" philosophy, controlling secondary market resales with activation code technology, and offering opportunities for technology upgrades. For customers, the systems allow for expansion of services, leverage physician time through delegable procedures, and are supported by a Customer Business Development program offering marketing and clinical support.

Recent Strategic Developments: In January 2024, Venus Concept Inc. launched its new Venus Prime program in North America, replacing its legacy subscription model. This program offers competitive financing rates, payment flexibility, and a seamless technology upgrade path for customers. In Q3 2022, the Company initiated a strategic shift to reduce reliance on subscription sales in the United States to improve cash generation and reduce bad debt exposure. The AI.ME platform received FDA 510(k) clearance for fractional skin resurfacing in December 2022, with the Medical Advisory Board currently evaluating new clinical applications. On January 24, 2024, the Board authorized a review of strategic alternatives to maximize shareholder value, including potential financings, mergers, asset sales, or licensing. The Company also implemented a restructuring plan in February 2023, involving workforce reductions, management changes, and the discontinuation of operations in unprofitable markets. Since June 2020, Venus Concept Inc. has ceased direct sales operations in 13 countries to increase focus on the United States market. In May and September 2024, portions of the MSLP Loan principal were converted into Series Y Convertible Preferred Stock. A 1-for-11 reverse stock split was effected on March 3, 2025.

Geographic Footprint: As of December 31, 2024, Venus Concept Inc. operated directly in 12 international markets through 10 direct offices located in the United States, Canada, Japan, Mexico, Spain, Germany, Australia, China, Hong Kong (majority-owned subsidiary), and Israel. The Company markets its technologies in over 60 countries across Europe, the Middle East, Africa, Asia-Pacific, and Latin America. Sales in markets outside the United States accounted for approximately 41% of total revenue in 2024 and 43% in 2023. The majority of the Company's research and development activities and system manufacturing are located outside the United States, primarily in Israel.

Financial Performance

Revenue Analysis

Profitability Metrics:

• Gross Margin: 68.3%
• Operating Margin: -41.9%
• Net Margin: -72.5%

Investment in Growth:

• R&D Expenditure: $6.7 million (10.3% of revenue)
• Capital Expenditures: $0.1 million
• Strategic Investments: The Company continues to invest in research and development to improve and enhance current technologies, products, and services, and to expand its product offering with new products and expanded indications. This includes the development of robotically assisted minimally invasive solutions for aesthetic procedures, such as the AI.ME platform, and ongoing efforts to broaden system applicators and advance its proprietary (MP)2 technology.

Business Segment Analysis

Venus Concept Inc. operates as a single operating segment, with its Chief Operating Decision Maker managing operations on a consolidated basis.

Revenue by Product Type:

• Leases (Venus Prime / Subscription—Systems): $13.3 million (-35.3% YoY)
• Products—Systems: $38.0 million (-9.2% YoY)
• Products—Other: $10.5 million (-0.9% YoY)
• Services: $3.1 million (-9.8% YoY)

Key Growth Drivers: The Company's growth strategy focuses on broadening its product portfolio by leveraging energy-based and robotic technologies, applying robotic technologies to new applications (e.g., AI.ME platform), and providing a comprehensive suite of products and services to the hair restoration market (ARTAS and NeoGraft). Strategic initiatives also include expanding regulatory cleared indications for products, penetrating non-traditional aesthetic markets, and enhancing international operations through direct sales and distributor networks.

Product Portfolio: Venus Concept Inc. offers twelve novel aesthetic technology platforms, including ARTAS and NeoGraft systems. Its aesthetic systems include Venus Legacy, Venus Versa, Venus Versa Pro, Venus Viva, Venus Viva MD, Venus Velocity, Venus Fiore, Venus Bliss, Venus Bliss Max, Venus Epileve, and AI.ME. Hair restoration solutions include ARTAS, ARTAS iX, and NeoGraft. The Company's core technologies include proprietary (MP)2 technology, Fractional Ablative RF, Intense Pulsed Light (IPL), Diode Lasers, Electrical Muscle Stimulation (EMS), and Micro-Coring. New products in development include ARTAS iX2 (next-generation hair restoration system) and Venus Nova (next-generation Venus Legacy product line).

Market Dynamics: The aesthetic and hair restoration markets are characterized by a continuous focus on body image, wide acceptance of procedures, and a shift towards broader availability of minimally and non-invasive treatments. Changing practitioner economics, driven by direct patient payments for elective procedures, are motivating providers to expand aesthetic practices. The Company's internal financing programs and cost-effective technologies aim to make treatment solutions more affordable, broadening the patient population.

Capital Allocation Strategy

Shareholder Returns: Venus Concept Inc. has never declared or paid cash dividends on its common stock and does not anticipate doing so in the foreseeable future, intending to retain any future earnings for business growth. No share repurchases were disclosed.

Balance Sheet Position: As of December 31, 2024, the Company had $4.3 million in cash and cash equivalents. Total debt obligations amounted to approximately $42.1 million, resulting in a net cash position of -$37.8 million. This compares to total debt obligations of $74.9 million and a net cash position of -$69.5 million as of December 31, 2023.

Debt Maturity Profile:

• Bridge Financing: $8.3 million due by April 30, 2025.
• MSLP Loan: $0.2 million due in 2025, and $3.0 million due in 2026.
• Madryn New Convertible Notes: $28.7 million due by December 9, 2026.
• EW Notes: $2.0 million due by December 9, 2026.

Cash Flow Generation: Cash used in operating activities was -$11.1 million in 2024, a 13.9% reduction from -$12.9 million in 2023. This improvement was primarily driven by a decrease in accounts receivable of $12.5 million and a decrease in inventories of $4.5 million. The Company's strategic shift to prioritize traditional cash sales over internal lease program sales is designed to enhance liquidity and reduce working capital requirements. The allowance for expected credit losses decreased from $7.4 million in 2023 to $3.8 million in 2024, representing 12.2% of gross outstanding accounts receivable.

Operational Excellence

Production & Service Model: Venus Concept Inc. utilizes two ISO-certified contract manufacturers in Karmiel, Israel, and Mazet, France, for the majority of its systems. The ARTAS System is assembled in San Jose, California, while reusable and disposable kits are assembled by NPI Solutions, Inc. in Morgan Hill, California. Over 85% of system production is located near the Company's research and development and operations facilities in Israel, allowing for control over the entire process from product development to final testing. The Company maintains a technical and clinical support team to address inquiries, troubleshoot product issues, and facilitate sales activities. Replacement systems, modules, and components are proactively deployed to strategic hubs globally to maximize customer "up time."

Supply Chain Architecture: Key Suppliers & Partners:

• Contract Manufacturers: Unnamed facilities in Karmiel, Israel, and San Jose, California; Electronique du Mazet in Mazet, France.
• Kit Assembler: NPI Solutions, Inc. in Morgan Hill, California, for ARTAS procedure kits.
• Component Suppliers: Relies on third-party suppliers for components and raw materials, with some sole-source suppliers for critical parts of the ARTAS System, reusable/disposable kits, and diode stacks. Supply Chain Dynamics: The Company experienced global supply chain disruptions and inflationary pressures through 2024, resulting in longer lead times and increased component and freight costs. Anticipates continued supply challenges in 2025 due to geopolitical disruptions in the Middle East impacting shipping lanes and production lead times. Mitigation strategies include price increases and margin management. Components are sourced from various countries, including China.

Facility Network:

• Principal Executive Offices: Toronto, Ontario, Canada (15,678 sq ft office, 2,134 sq ft warehouse, lease expires August 31, 2030).
• Research & Development/Manufacturing/Logistics: San Jose, California (approx. 30,011 sq ft, lease expires July 14, 2027).
• Research & Development: Yokne’am Illit, Israel (approx. 530 sq meters, lease expires September 30, 2025, with a 12-month extension option).
• Distribution: Davie, Florida (approx. 4,733 sq ft, lease expires November 30, 2025).

Operational Metrics: The Company's manufacturing processes and facilities comply with ISO:13485:2016, CE (MDD→MDR), and MDSAP quality management system regulations, and are subject to periodic inspections by regulatory authorities.

Market Access & Customer Relationships

Go-to-Market Strategy: Distribution Channels:

• Direct Sales: Utilizes an internal direct sales force in North America and select international markets, including Japan, Mexico, Spain, Germany, Israel, Australia, China, and Hong Kong.
• Channel Partners: Engages third-party distributors in over 40 countries where direct operations are not established. These agreements typically include minimum quarterly purchase commitments.
• Digital Platforms: Employs online sales channels and e-commerce initiatives, including a presence on major social media platforms (Facebook, Twitter, YouTube, Pinterest, LinkedIn, Instagram) and online promotions.

Customer Portfolio: Enterprise Customers: The Company targets both traditional aesthetic providers (plastic surgeons, dermatologists) and non-traditional markets (general and family practitioners, aesthetic medical spas). Customer Concentration: No single customer accounted for more than 10% of the Company's revenue or accounts receivable in either 2024 or 2023, indicating a diversified customer base.

Geographic Revenue Distribution:

• United States: 58.9% of total revenue in 2024 ($38.2 million)
• International: 41.1% of total revenue in 2024 ($26.7 million) Growth Markets: The Company continues to focus its direct sales efforts in the North America market and strategically evaluates and optimizes its use of direct and distributor resources in international markets.

Competitive Intelligence

Market Structure & Dynamics

Industry Characteristics: The medical technology and aesthetic product markets are highly competitive and dynamic, characterized by rapid technological development and product innovation. The aesthetic industry is particularly vulnerable to unfavorable economic trends, as treatments are elective and typically not covered by insurance. Recent consolidation in the aesthetic industry has led to combined entities with greater financial resources, deeper sales channels, and increased pricing flexibility.

Competitive Positioning Matrix:

Direct Competitors

Primary Competitors:

• Aesthetic Market: Companies offering minimally invasive and non-invasive medical aesthetic procedures, as well as conventional non-energy-based treatments such as neurotoxins, dermal fillers, chemical peels, and microdermabrasion.
• Surgical Hair Restoration Market: Traditional Follicular Unit Transplantation (FUT Strip Surgery) and Manual Follicular Unit Extraction (FUE) procedures.
• General Medical Technology and Aesthetic Companies: Larger entities with greater capital resources, extensive sales and marketing operations, and established relationships with physicians.

Emerging Competitive Threats: The market faces threats from new entrants, disruptive technologies, and alternative solutions. Competitors in international markets may benefit from less stringent regulatory requirements and fewer limitations on product claims and marketing.

Competitive Response Strategy: Venus Concept Inc. aims to maintain its competitive advantage through continuous innovation and development of new products, services, and applications. This includes expanding clinical support, nurturing relationships with industry thought leaders, increasing market awareness of new products, and bolstering international sales and marketing capabilities.

Risk Assessment Framework

Strategic & Market Risks

Market Dynamics: The Company is exposed to risks from unfavorable macroeconomic conditions, including global economic volatility, inflation, rising interest rates, and foreign currency impacts, which can reduce demand for elective aesthetic procedures and strain customer financing capabilities. Rapid technological development and product innovation in the aesthetic market pose a risk of competitive deterioration if the Company cannot continuously develop and commercialize new products and enhancements. The difficulty in forecasting future performance due to the rapid evolution of medical technology and aesthetic markets can lead to unpredictable financial results.

Operational & Execution Risks

Supply Chain Vulnerabilities: Reliance on a limited number of third-party contract manufacturers and, in some cases, sole suppliers for critical components, exposes the Company to supply shortages, price fluctuations, and potential inability to meet demand. Geographic concentration of manufacturing operations in Israel creates exposure to political, economic, and military conditions, including the Israel-Hamas conflict, which could disrupt facilities, damage inventory, and delay product delivery. Product Liability: The Company faces the risk of product liability suits for defective design, manufacturing, labeling, software, or misuse of its systems, which could result in substantial litigation costs, damages, increased insurance rates, and reputational harm. Cybersecurity: The Company relies on software for system control and handling sensitive data, making its information technology systems vulnerable to cyberattacks, breaches, and human error. Such incidents could lead to significant costs, operational interruptions, reputational damage, litigation, and regulatory fines.

Financial & Regulatory Risks

Market & Financial Risks: Recurring net operating losses and negative cash flows raise substantial doubt about the Company's ability to continue as a going concern, necessitating additional equity or debt financing. Internal financing programs expose the Company to credit risk from customers. Loan and security agreements contain restrictive covenants that limit financial and operational flexibility, with non-compliance potentially triggering events of default. The Company is also exposed to foreign exchange risk due to a significant portion of expenses being denominated in foreign currencies (NIS, CAD) while revenues are primarily in USD, and generally does not engage in currency hedging. Regulatory & Compliance Risks: The Company's devices and operations are subject to extensive government regulation by the FDA in the United States and foreign regulatory agencies globally. Failure to comply with these complex and evolving requirements (e.g., design, manufacturing, testing, marketing, post-market surveillance, export controls) could result in fines, injunctions, product recalls, withdrawal of marketing clearances, and other enforcement actions. Restrictions on marketing for off-label uses and medical device reporting obligations are also significant compliance areas.

Geopolitical & External Risks

Geopolitical Exposure: A significant portion of the Company's operations, including R&D facilities and key third-party suppliers, are located in Israel. This exposes the business to political, economic, and military conditions in the region, including the ongoing Israel-Hamas conflict, which could adversely affect operations, supply chains, and the ability to deliver products. The Company's insurance does not cover losses from events associated with the security situation in the Middle East.

Innovation & Technology Leadership

Research & Development Focus: Core Technology Areas: Venus Concept Inc. focuses its R&D on proprietary energy-based technologies, including (MP)2 (multipolar RF and magnetic pulse synthesizers) for non-invasive skin tightening, wrinkle reduction, body contouring, cellulite, and fat reduction. Other key technologies include fractional ablative RF, Intense Pulsed Light (IPL), diode lasers, Electrical Muscle Stimulation (EMS), and micro-coring. The Company also emphasizes robotic technology, exemplified by the ARTAS System for hair transplantation and the AI.ME platform for fractional skin resurfacing. Innovation Pipeline: The R&D pipeline is dedicated to improving and enhancing current technologies, products, and services, as well as expanding the product offering with new products and indications. This includes the development of robotically assisted minimally invasive solutions for aesthetic procedures, with the AI.ME platform's Medical Advisory Board evaluating new clinical applications such as loose skin, striae, and scars. Future products in development include ARTAS iX2, the next-generation ARTAS Hair Restoration system, and Venus Nova, the next generation of the Venus Legacy product line.

Intellectual Property Portfolio:

• Patent Strategy: The Company relies on a combination of patent, copyright, trademark, and trade secret laws to protect its intellectual property. As of December 31, 2024, its patent portfolio included 16 issued U.S. patents, 4 pending U.S. patent applications, 31 issued foreign counterpart patents, and 12 pending foreign counterpart patent applications covering (MP)2, fractional RF, AI.ME, and Directional Skin Tightening technology. Additionally, it held 4 issued foreign patents for the NeoGraft system and 92 issued U.S. patents, 176 issued foreign counterpart patents, and 4 pending foreign counterpart patent applications for the ARTAS System.
• Licensing Programs: Venus Concept Inc. holds an exclusive, worldwide license from HSC Development LLC and James A. Harris, M.D., for the development, manufacture, and commercialization of products utilizing computer-controlled systems for hair removal and implantation, under which the ARTAS System was developed. The licensed patents expire between 2025 and 2030.

Technology Partnerships: The Company engages in collaboration with an experienced robotic research and development team in the United States and is actively investigating partnering opportunities for applying its robotics technologies across a wide range of aesthetic procedures.

Leadership & Governance

Executive Leadership Team

Information regarding the Executive Leadership Team is incorporated by reference to the Company's Proxy Statement with respect to its 2024 Annual Meeting of Stockholders.

Human Capital Strategy

Workforce Composition: As of December 31, 2024, Venus Concept Inc. had a total of 292 full-time employees. The workforce is geographically distributed with 128 employees in the United States, 69 in Canada, 33 in Israel, and 62 in the rest of the world. Approximately 75 employees were direct sales representatives and sales management.

Talent Management: The Company's success is dependent on its ability to recruit, hire, train, and retain qualified sales professionals, senior management, and key employees. It provides comprehensive clinical training and practice-based marketing support for physicians, including the specialized VeroHair 12 Step Program for ARTAS and NeoGraft customers, along with quarterly educational webinars and remote consultations.

Environmental & Social Impact

Environmental Commitments: Venus Concept Inc. is subject to various foreign, federal, state, and local environmental, health, and safety laws and regulations concerning safe working conditions, product stewardship, and environmental protection, including those governing hazardous materials. Compliance costs have not been material to date.

Business Cyclicality & Seasonality

Demand Patterns: The Company's financial results can fluctuate due to seasonal or other variations in patient demand for aesthetic procedures. The aesthetic industry is particularly sensitive to economic conditions, as treatments are elective and not covered by government or private health insurance, making patient demand susceptible to economic uncertainty or recession.

Regulatory Environment & Compliance

Regulatory Framework: Venus Concept Inc.'s medical devices and operations are subject to extensive government regulation and oversight by numerous authorities, including the FDA in the United States and corresponding state and foreign regulatory agencies. This regulation covers all aspects of medical device lifecycle, from design and development to manufacturing, testing, marketing, sales, distribution, and post-market surveillance. Compliance with these regulations, which are complex and tend to become more stringent, is critical for market access and continued operations. International Compliance: The Company must navigate diverse regulatory schemes and clearance processes in over 60 countries, with device indications varying by market. The European Economic Area (EEA) requires compliance with the Medical Devices Directive and the new Medical Devices Regulation (MDR), which significantly strengthens requirements for clinical evaluation and post-market surveillance. Trade & Export Controls: The Company is subject to import and export requirements, anti-corruption laws (such as the Foreign Corrupt Practices Act), anti-bribery laws, tax laws, foreign exchange controls, data privacy and security requirements, environmental laws, labor laws, and anti-competition regulations across its international operations. Legal Proceedings: As of December 31, 2024, Venus Concept Inc. was not party to any material active or pending legal proceedings.

Tax Strategy & Considerations

Tax Profile: The Company's effective tax rate differs from the federal statutory rate primarily due to differences in jurisdictional tax rates, a valuation allowance, and non-deductible expenses. As of December 31, 2024, the Company had deferred tax assets of $1.5 million and no deferred tax liabilities. A valuation allowance of $80.4 million was recorded to reduce deferred tax assets. The Company had federal, state, and foreign non-operating loss (NOL) carryforwards of approximately $56.1 million and federal and state research and development credit carryforwards of approximately $1.0 million. Unrecognized tax benefits amounted to $0.1 million.

Insurance & Risk Transfer

Risk Management Framework: Venus Concept Inc. maintains product liability insurance; however, there is a risk that claims could exceed coverage limits or fall under policy exclusions. Notably, the Company's insurance does not cover losses that may arise from events associated with the security situation in the Middle East or any resulting disruption to its operations.